News

Morgan Stanley and private equity investors Actis Advisors and Sequoia Capital India Advisors, which jointly own 70% in Paras Pharma, are also said to be in the race.

Jevtana, a microtubule inhibitor, is approved in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen.

The article, entitled ‘A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain,’ has been published in Pain, the

Previously, Cortex Pharma signed a research agreement with Organon, now a subsidiary of Merck, providing Organon an exclusive, worldwide right to develop and commercialise the schizophrenia and depression

Berlin, Germany-based caprotec bioanalytics focuses on the commercialisation of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. Prior to joining caprotec, Metternich was the vice president and head

Prior to being named as Rondaxe Enterprises’ CEO, Shultis was responsible for the company’s Software Development and Pharma Consulting groups, where he oversaw a myriad of services including

The total contract value for Galapagos for the initial phase of the collaboration could exceed €33.5m over a 5 year period pending the achievement of certain milestones. As

The grant is expected to support the next stages of development for Embera’s drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing.

Elan said that its Manufacturing Services offers an advantage in outsourcing, including a broad range of services and expertise integrated to one company that is based in the